Dedicated Breast MR Imaging System Distinguishes Between Tumor and Normal Fat Tissue

Publication
Article
OncologyONCOLOGY Vol 9 No 5
Volume 9
Issue 5

he development and testing of a new method of high quality clinical fat/water separated 3D breast MR images was recently announced by Advanced NMR Systems Inc., with its subsidiary, Advanced Mammography Systems Inc.

he development and testing of a new method of high quality clinicalfat/water separated 3D breast MR images was recently announcedby Advanced NMR Systems Inc., with its subsidiary, Advanced MammographySystems Inc.

This new technique, used in conjunction with their imaging technologyfor breast diagnosis, suppresses the signal from fatty tissue,and allows MR imaging to distinguish tumor from normal fat breasttissue. In contrast, conventional nondedicated MR imaging generallycannot distinguish between tumor and normal fat breast tissue.

This new method also reduces breast imaging to under 6 minutes,according to the company, thereby increasing patient comfort.

A patent application for this technique is currently being processedfor filing. Advanced Mammography Systems Inc. has completed aprototype of its dedicated MR mammography system, and is currentlynegotiating with medical facilities for its installation. Thecompany has filed for Food and Drug Administration clearance forcommercial use of this system.

Recent Videos
Patients with lung cancer who achieve a complete response with neoadjuvant therapy may not experience additional benefit with adjuvant immunotherapy.
Numerous trials have displayed the evolution of EGFR inhibition alone or with chemotherapy/radiation in the EGFR-mutated lung cancer space.
2 experts are featured in this series.
Although high grade adverse effects are infrequent among patients undergoing treatment for SCLC, CRS and ICANS may occur in higher frequencies.
Two experts are featured in this series.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 67th Annual ASH Meeting in Orlando.
4 experts are featured in this series.
Based on a patient’s SCLC subtype, and Schlafen 11 status, patients will be randomly assigned to receive durvalumab alone or with a targeted therapy in the S2409 PRISM trial.
4 experts are featured in this series.
Daniel Peters, MD, aims to reduce the toxicity associated with AML treatments while also improving therapeutic outcomes.
Related Content